Clinical Trial: Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07468071) titled 'Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments' on March 09.

Brief Summary: The purpose of this study is to allow continued access to opnurasib (JDQ443) to participants who are benefitting from treatment with opnurasib as a single agent or in combination with other study treatments in pre-defined Novartis-sponsored opnurasib studies and to continue to assess safety in these participants.

Study Start Date: June 24, 2026

Study Type: INTERVENTIONAL

Condition: Locally Advanced or Metastatic KRAS G12C-mutated Non-...